Form 8-K Akebia Therapeutics, For: Aug 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Akebia Therapeutics (AKBA) PT Raised to $7.50 at H.C. Wainwright
August 12, 2024 6:13 AM EDTH.C. Wainwright analyst Ed Arce raised the price target on Akebia Therapeutics (NASDAQ: AKBA) to $7.50 (from $6.00) while maintaining a Buy rating.
The analyst comments "Akebia is focused on the long game, with pre-commercial execution preparing for Vafseo as the standard-of-care. As previously announced, Akebia submitted its TDAPA application in June. Akebia expects to have a CPT code assigned in October 2024 and full TDAPA designation by January 1, 2025. In... More
